Investors are excited about two new products for the genetic testing and liquid biopsy developer.
News & Analysis: Natera
NTRA earnings call for the period ending March 31, 2019.
The genetic testing leader announced full-year 2018 operating results, but the numbers were actually pretty poor.
NTRA earnings call for the period ending December 31, 2018.
Here's why these stocks are making moves in after-hours trading.
Here's what's pushing up the top-performing, non-pharmaceutical healthcare stocks.
Shares jump in response to two bullish analyst notes. Here's what investors need to know.
The non-invasive genetic screening company tests are gaining popularity.
Shares fall hard in response to the release of a less than stellar earnings report.
News of the company gaining a foothold overseas puts investors in a good mood.